Welcome!

News Feed Item

Astellas Pharma EMEA Announces New Senior Appointments

CHERTSEY, England, August 7, 2014 /PRNewswire/ --

Astellas Pharma EMEA, the regional headquarters of Astellas Pharma Inc. for Europe, the Middle East and Africa, has appointed Simon Dew to the position of Chief Strategy Officer from his previous role as Vice President: Business and Commercial Development. Simon succeeds Naoki Okamura, who after over two years in the post has moved to the Company's global headquarters in Tokyo as Corporate Vice President, Licensing & Alliances. Simon's senior team will be joined by Jun Kono, who has been appointed Vice President: Corporate Strategy and Communications.

     (Logo: http://photos.prnewswire.com/prnh/20140522/689211 )
     (Photo: http://photos.prnewswire.com/prnh/20140807/700728-a )

     (Photo: http://photos.prnewswire.com/prnh/20140807/700728-b )

Astellas is the second largest pharmaceutical company in Japan and among the top 20 globally. It is growing strongly in the EMEA region, with an 8.1% rise in sales to €1,967 million in FY2013. The Company's rigorous prioritisation of research and development (R&D) to produce innovative medicines that provide new standards of care for patients and their doctors, has seen a range of therapies recently launched in the region, including new classes of treatment for advanced prostate cancer, overactive bladder and the hospital-acquired infection, Clostridium difficile.

Ken Jones, President and CEO Astellas Pharma EMEA, commented: "These are important appointments to our strong senior leadership team as we review our strategic direction to support the Company's continued success.  Simon has made a significant contribution to Astellas since joining eight years ago - helping ensure the Company is on track to reach goals set in our business blueprint, VISION 2015, in terms of our therapeutic focus, pipeline and sales. He has supported the region's excellent financial performance, which has seen three consecutive years of growth despite a challenging industry environment and continued austerity.  Jun brings a wealth of experience in corporate strategy and planning, and we are delighted that he is returning to the EMEA from our Head Office in Japan." 

As Chief Strategy Officer, Simon will play a major role in the EMEA region by helping steer Astellas as it continues to evolve its portfolio of therapies in priority disease areas. In particular, Astellas aims to further enhance its leadership in Urology and Transplantation, whilst developing a new cancer drugs portfolio to meet the Company's objective of achieving global category leadership in Oncology. Nearly a fifth of global sales are invested in R&D in a multi-track approach that combines in-house drug discovery, in-licensing and collaborations with a wide range of research organisations.

In his new role Simon will oversee Business Development, Alliance Management, Commercial Development, and Corporate Strategy and Communications, leading a team of around 18 specialists across these functions. With 25 years in the industry and a wealth of experience in commercial development strategies and managing alliances/acquisitions, Simon's expertise will help Astellas maintain the innovative and productive pipeline that has become its hallmark.

Jun takes on leadership of Astellas Pharma EMEA's Corporate Strategy and Communications and will be responsible for guiding the strategic direction of the Company's mid-term plan, product portfolio and commercial operations. He will also lead development of Astellas' growing profile in the EMEA region, building the Company's corporate brand through communications targeting a wide range of internal and external stakeholders. In addition, Jun will be responsible for planning and directing Astellas Pharma EMEA's programme of corporate social responsibility (CSR) initiatives.

Notes to Editors 

About Simon Dew 

Simon joined Astellas in 2006, shortly after the Company was established, as Senior Manager Business Development. As well as establishing specialist EMEA commercial and business development capabilities and building the Company's profile as a partner of choice, Simon has provided strategic direction and managed external alliances to ensure the pipeline supports priority franchise areas and delivers new products that meet approval and reimbursement requirements across European markets. Under his leadership, his team played a significant role in the commercialisation of XTANDI (enzalutamide), a new treatment for advanced prostate cancer, developed in partnership with Medivation, which is a pivotal part of Astellas' growing oncology portfolio.

Simon originally qualified as a pharmacist and has broad experience in the pharmaceutical and biotech industry through previous roles at Quintiles Transnational, PAREXEL International, Phytopharm, SmithKline Beecham and Bristol Myers Squibb.

About Jun Kono 

Jun was appointed to a strategic planning role at Yamanouchi in 2003, where he was a key member of the merger-integration project to form Astellas in 2005. Since then he has expanded his expertise in corporate strategy and business development, through his engagement in projects for corporate vision, company acquisition and in/out licensing of various assets. His most recent role as Vice President: Head of Executive Office at the Company's Tokyo headquarters focused on corporate senior global management, including work with senior leaders to enhance operational performance thorough cross-functional collaboration.  Jun has worked both in Japan and the UK, and between 2006 and 2010 was Associate Director, Strategic Planning for the EMEA region.

Jun received a Master of Business Administration (Hons.) from the University of Chicago Booth School of Business. 

About Astellas Pharma EMEA  

Astellas Pharma EMEA operates in 40 countries across Europe, the Middle East and Africa, and is the regional business of Tokyo-based Astellas Pharma Inc. Astellas is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceuticals. The organisation's focus is to deliver outstanding R&D and marketing to continue growing in the world pharmaceutical market. Astellas presence in Europe also includes an R&D site and three manufacturing plants. The company employs approximately 4,350 staff across these regions. For more information about Astellas Pharma EMEA, please visit http://www.astellas.eu.

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
SYS-CON Events announced today that Enzu will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY, and the 21st International Cloud Expo®, which will take place October 31-November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Enzu’s mission is to be the leading provider of enterprise cloud solutions worldwide. Enzu enables online businesses to use its IT infrastructure to their competitive ad...
This talk centers around how to automate best practices in a multi-/hybrid-cloud world based on our work with customers like GE, Discovery Communications and Fannie Mae. Today’s enterprises are reaping the benefits of cloud computing, but also discovering many risks and challenges. In the age of DevOps and the decentralization of IT, it’s easy to over-provision resources, forget that instances are running, or unintentionally expose vulnerabilities.
Everywhere we turn in our industry we can find strong opinions about the direction, type and nature of cloud’s impact on computing and business. Another word that is used in every context in our industry is “hybrid.” In his session at 20th Cloud Expo, Alvaro Gonzalez, Director of Technical, Partner and Field Marketing at Peak 10, will use a combination of a few conceptual props and some research recently commissioned by Peak 10 to offer a real-world consideration of how the various categories of...
DevOps is often described as a combination of technology and culture. Without both, DevOps isn't complete. However, applying the culture to outdated technology is a recipe for disaster; as response times grow and connections between teams are delayed by technology, the culture will die. A Nutanix Enterprise Cloud has many benefits that provide the needed base for a true DevOps paradigm. In his Day 3 Keynote at 20th Cloud Expo, Chris Brown, a Solutions Marketing Manager at Nutanix, will explore t...
In his opening keynote at 20th Cloud Expo, Michael Maximilien, Research Scientist, Architect, and Engineer at IBM, will motivate why realizing the full potential of the cloud and social data requires artificial intelligence. By mixing Cloud Foundry and the rich set of Watson services, IBM's Bluemix is the best cloud operating system for enterprises today, providing rapid development and deployment of applications that can take advantage of the rich catalog of Watson services to help drive insigh...
SYS-CON Events announced today that SoftLayer, an IBM Company, has been named “Gold Sponsor” of SYS-CON's 18th Cloud Expo, which will take place on June 7-9, 2016, at the Javits Center in New York, New York. SoftLayer, an IBM Company, provides cloud infrastructure as a service from a growing number of data centers and network points of presence around the world. SoftLayer’s customers range from Web startups to global enterprises.
When NSA's digital armory was leaked, it was only a matter of time before the code was morphed into a ransom seeking worm. This talk, designed for C-level attendees, demonstrates a Live Hack of a virtual environment to show the ease in which any average user can leverage these tools and infiltrate their network environment. This session will include an overview of the Shadbrokers NSA leak situation.
In his keynote at @ThingsExpo, Chris Matthieu, Director of IoT Engineering at Citrix and co-founder and CTO of Octoblu, focused on building an IoT platform and company. He provided a behind-the-scenes look at Octoblu’s platform, business, and pivots along the way (including the Citrix acquisition of Octoblu).
Multiple data types are pouring into IoT deployments. Data is coming in small packages as well as enormous files and data streams of many sizes. Widespread use of mobile devices adds to the total. In this power panel at @ThingsExpo, moderated by Conference Chair Roger Strukhoff, panelists will look at the tools and environments that are being put to use in IoT deployments, as well as the team skills a modern enterprise IT shop needs to keep things running, get a handle on all this data, and deli...
As enterprise cloud becomes the norm, businesses and government programs must address compounded regulatory compliance related to data privacy and information protection. The most recent, Controlled Unclassified Information and the EU’s GDPR have board level implications and companies still struggle with demonstrating due diligence. Developers and DevOps leaders, as part of the pre-planning process and the associated supply chain, could benefit from updating their code libraries and design by in...
Five years ago development was seen as a dead-end career, now it’s anything but – with an explosion in mobile and IoT initiatives increasing the demand for skilled engineers. But apart from having a ready supply of great coders, what constitutes true ‘DevOps Royalty’? It’ll be the ability to craft resilient architectures, supportability, security everywhere across the software lifecycle. In his keynote at @DevOpsSummit at 20th Cloud Expo, Jeffrey Scheaffer, GM and SVP, Continuous Delivery Busine...
DevOps is often described as a combination of technology and culture. Without both, DevOps isn't complete. However, applying the culture to outdated technology is a recipe for disaster; as response times grow and connections between teams are delayed by technology, the culture will die. A Nutanix Enterprise Cloud has many benefits that provide the needed base for a true DevOps paradigm.
With major technology companies and startups seriously embracing Cloud strategies, now is the perfect time to attend @CloudExpo | @ThingsExpo, June 6-8, 2017, at the Javits Center in New York City, NY and October 31 - November 2, 2017, Santa Clara Convention Center, CA. Learn what is going on, contribute to the discussions, and ensure that your enterprise is on the right path to Digital Transformation.
SYS-CON Events announced today that EARP Integration will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. EARP Integration is a passionate software house. Since its inception in 2009 the company successfully delivers smart solutions for cities and factories that start their digital transformation. EARP provides bespoke solutions like, for example, advanced enterprise portals, business intelligence systems an...
SYS-CON Events announced today that WineSOFT will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Based in Seoul and Irvine, WineSOFT is an innovative software house focusing on internet infrastructure solutions. The venture started as a bootstrap start-up in 2010 by focusing on making the internet faster and more powerful. WineSOFT’s knowledge is based on the expertise of TCP/IP, VPN, SSL, peer-to-peer, mob...